Evert (Eef) Schimmelpennink was appointed Chief Executive Officer, President and Secretary of Pfenex on August 3, 2017.
Eef is a senior commercial leader with extensive global Biosimilar, Generics and Pharmaceutical expertise in commercial planning, pipeline development, legal and regulatory strategy, business development and new product launches. He has been delivering shareholder value by focusing on execution of well-defined strategy based on aligning Commercial, R&D and Manufacturing.
Prior to joining Pfenex Eef was the CEO of Alvotech, a biosimilar development and manufacturing company. Before that he served as Vice President Global Sterile Injectables of Pfizer and held several leadership roles at Hospira, most recently as Vice President Global Generics. Prior to joining Hospira, Eef held roles of increasing responsibility in marketing and sales, product management and R&D at Synthon, Numico and RIVM. He began his career in the healthcare industry in 1997.
Patrick K. Lucy
Patrick Lucy, a member of the founding team at Pfenex, has served as our Chief Business Officer since 2009. Prior to joining Pfenex, Mr. Lucy held the position of Director of Business Development at DowPharma, a business within The Dow Chemical Company, a chemicals manufacturer, from 2002 to 2009. From 1999 to 2002, he held the position of Director of Business Development at Collaborative BioAlliance, Inc., a biotechnology company, which was acquired by The Dow Chemical Company. From 1996 to 1999, Mr. Lucy worked at Lonza Biologics Inc. a chemicals and biotechnology company. While at Lonza Mr. Lucy held roles spanning Quality, Operations and Capital Project Management, playing a key role in the design, construction and commissioning of large scale biologics manufacturing facilities. From 1991 to 1996, Mr. Lucy worked at Repligen Corporation, a life sciences company, in various leadership roles focused on biochemistry.
Mr. Lucy holds a Bachelor’s degree in Biology from Villanova University.
Paul A. Wagner
Paul Wagner joined us in April 2014 as our Chief Financial Officer. Prior to joining us, Dr. Wagner held the position of Director and Portfolio Manager/Sr. Equity Analyst with Allianz Global Investors, a diversified active investment manager where he worked from 2006 to 2014. Prior to that, Dr. Wagner was the Head of Development Licensing at PDL BioPharma, a diversified biopharmaceutical company from 2005 until 2006. Prior to PDL BioPharma, Dr. Wagner held the position of Vice President at Lehman Brothers, a global financial services firm, starting in 1999 until 2005.
Dr. Wagner received a B.S. from the University of Wisconsin and a Ph.D. in Chemistry from the California Institute of Technology. Dr. Wagner is also a CFA charterholder.
Patricia Lady has served as our Chief Accounting Officer since 2011. Prior to serving in her current role, Ms. Lady served as our Director of Finance and Corporate Controller from 2009 to 2011. From 2007 to 2009, she served as Director of Finance and Accounting at Neurocrine Biosciences, Inc., a biopharmaceutical company. From 2006 to 2007, Ms. Lady held the position of Corporate Controller of Avanir Pharmaceuticals, Inc., a pharmaceutical company. From 2001 to 2005, Ms. Lady held the position of Vice President of Finance at 3E Company, a technology company. From 2000 to 2001, she served as Vice President of Business Development of Everypath, Inc., a technology company. From 1999 to 2000, Ms. Lady held the position of Vice President of Business Development and Marketing at iOwn, Inc., a technology company. From 1997 to 1999, she served as Vice President of Business Development at Careerbuilder, a technology company. Ms. Lady is a certified public accountant, a chartered global management accountant and a certified management accountant.
Ms. Lady holds a Bachelor’s degree in Accounting from California State University, Fullerton and an M.B.A. from the University of California, Los Angeles.
Hubert C. Chen
Hubert Chen has served as Pfenex’s Chief Medical and Scientific Officer since November 2014. Previously, Dr. Chen served as vice president of clinical development at Aileron Therapeutics, where he led the first IND filing and clinical investigation for the Stapled Peptide technology. He also oversaw the early clinical and regulatory activities for a first-in-class MDM2/MDMX dual inhibitor for malignancies expressing wild-type p53 tumor suppressor protein. Before Aileron, Dr. Chen was vice president of translational medicine at Regulus Therapeutics, where he provided preclinical and clinical strategies for microRNA-based medicines in multiple therapeutic areas, including atherosclerosis, diabetes, fibrosis, and hepatitis C infection. Before Regulus, Dr. Chen was senior director of clinical research at Amylin Pharmaceuticals, where he was responsible for the development of second-generation obesity and diabetes programs. He started his biotech career as associate director of medical sciences at Amgen.
Dr. Chen was staff research investigator at the Gladstone Institutes and assistant clinical professor of medicine at the University of California, San Francisco. He received his residency training at Massachusetts General Hospital, M.D. from Columbia University, and B.A.S. in political sciences and biological sciences from Stanford University. Dr. Chen is board certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism.
Mayda Mercado joined Pfenex in 2016 as Vice President of Global Quality. Mayda is a Quality & Compliance leader with over 25 years of progressive leadership background in the biopharmaceutical/ pharmaceutical and health care industry, bringing a diverse and broad experience to the team that includes serving most recently as Independent Consultant in Quality & Compliance in the US and Brazil. Previously, she served as Vice President of Quality at Therapeutic Proteins Inc., Biosimilar startup Company with responsibilities for Quality and Compliance. She previously worked at Merck, as Executive Director, Global Biologics Quality Operations with responsibilities in Quality & Compliance for the Biologics network including Biologics Bulk Drug Substances, (DS) Active Product Ingredients (API’s), external contract manufacturing, contract laboratories and Sterile finished products for clinical, commercialization and commercial operations.
Mayda led the Quality/ Compliance journey and pre-approval site GMP inspection readiness for Keytruda (pembrolizumab), Merck’s antibody that was designated Breakthrough status by the FDA and subsequently approved. Previously, she worked at Pfizer (formerly Wyeth), as AVP Quality & Compliance responsible for Biopharma Global Quality Products and as a Site Quality Head responsible for Quality Operations/ Compliance and led transformation efforts while maintained high standard regulatory profile. Prior of joining Wyeth, she spent several years at Johnson & Johnson in positions including Director, Supply Chain Processes, at Global Supply Chain, LLC, Director of Compliance at, Centocor Inc., Quality Management Team SAP at Janssen Pharmaceutical Sourcing Group, QC Manager at Ortho Biologics. Mayda extensive experience will support our team in the execution of commercialization.